Skip to content

Viatris VTRS Net Income

Net Income at other companies

Pfizer logo
PfizerPFE
$2.69B-9.4%
McKesson logo
McKessonMCK
$1.68B+33.5%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$29.49M+88.1%
Cencora logo
CencoraCOR
$1.64B+129%
AMP
Amphastar PharmaceuticalsAMPH
$6.42M-74.6%
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
-$8.06M+64.9%

Other financials

Income statement

See full
Revenue$3.5B+8.1%
Gross profit$1.2B-0.3%
Operating income-$79.7M+97.2%
EPS (diluted)$0.15+106%

Balance sheet

See full
Cash & equivalents$1.8B+139%
Total debt$14.6B+1.0%
Total equity$14.7B-6.3%
Total assets$36.8B-4.3%

Cash flow

See full
Operating cash flow$388.3M-27.5%
CapEx$39.9M-6.3%
Free cash flow$348.4M-29.3%

Valuation

See full
Market cap$18.49B+81.7%
Enterprise value$31.3B+29.5%
P/S1.3×+0.5×

Profitability

See full
Gross margin34.4%-2.5pp
Operating margin1%
Net margin-2%-1.0pp
FCF margin12.3%-1.0pp

Returns & leverage

See full
Return on equity-2%-0.9pp
Debt / equity+0.1×
Current ratio1.6×-0.1×

Where this comes from

Reported directly by Viatris in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic.

The official record: Viatris’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Viatris's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Viatris's net income?
Viatris (VTRS) reported net income of $176.4M in Q1 2026.
How has Viatris's net income changed year-over-year?
Viatris's net income increased by 105.8% year-over-year, from -$3.04B to $176.4M.
What is the long-term trend for Viatris's net income?
Over 3 years (2021 to 2025), Viatris's net income has grown at a 40.4% compound annual growth rate (CAGR), from -$1.27B to -$3.51B.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.